Literature DB >> 2189084

Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.

J H Noseworthy1, M K Vandervoort, C J Wong, G C Ebers.   

Abstract

We describe the interrater variability in the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. Two physicians blinded to their previous assessments and to each other's scores consecutively examined 168 patients (545 paired examinations). Perfect agreement on the assignment of the disability scores ranged from 48% (cerebellar functional group) to 69% (EDSS and pyramidal functional group). Only 31% to 62% of this agreement occurred independently of that expected by chance (kappa). With the exception of the cerebellar and sensory functional groups, agreement within 1 step occurred in at least 92% of cases. These findings suggest that differences of a single step on these scales may not reflect an important functional change. We recommend that at least a 2-step change (1.0 point on the EDSS and 2 points on the FS) is needed to be confident of an important change in the degree of disability or response to treatment in this disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2189084     DOI: 10.1212/wnl.40.6.971

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  69 in total

1.  Walking function in clinical monitoring of multiple sclerosis by telemedicine.

Authors:  Núria Sola-Valls; Yolanda Blanco; Maria Sepúlveda; Sara Llufriu; Elena H Martínez-Lapiscina; Delon La Puma; Francesc Graus; Pablo Villoslada; Albert Saiz
Journal:  J Neurol       Date:  2015-05-10       Impact factor: 4.849

2.  European validation of a standardized clinical description of multiple sclerosis.

Authors:  Maria Pia Amato; Jerome Grimaud; Iuliana Achiti; Maria Letizia Bartolozzi; Patrice Adeleine; Hans-Peter Hartung; Ludwig Kappos; Alan Thompson; Maria Trojano; Sandra Vukusic; Christian Confavreux
Journal:  J Neurol       Date:  2004-12       Impact factor: 4.849

Review 3.  Cyclophosphamide for multiple sclerosis.

Authors:  L La Mantia; C Milanese; N Mascoli; R D'Amico; B Weinstock-Guttman
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

4.  Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.

Authors:  D H Miller; F Barkhof; I Berry; L Kappos; G Scotti; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-08       Impact factor: 10.154

Review 5.  Clinical prognostic factors in multiple sclerosis: a natural history review.

Authors:  Alexandra Degenhardt; Sreeram V Ramagopalan; Antonio Scalfari; George C Ebers
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

6.  Impact of multiple sclerosis relapses on progression diminishes with time.

Authors:  H Tremlett; M Yousefi; V Devonshire; P Rieckmann; Y Zhao
Journal:  Neurology       Date:  2009-11-04       Impact factor: 9.910

Review 7.  Does a placebo-effect exist in clinical trials on multiple sclerosis? Review of the literature.

Authors:  L La Mantia; M Eoli; A Salmaggi; C Milanese
Journal:  Ital J Neurol Sci       Date:  1996-04

8.  Precision and reliability for measurement of change in MRI lesion volume in multiple sclerosis: a comparison of two computer assisted techniques.

Authors:  P D Molyneux; P S Tofts; A Fletcher; B Gunn; P Robinson; H Gallagher; I F Moseley; G J Barker; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-07       Impact factor: 10.154

9.  Contribution of relapses to disability in multiple sclerosis.

Authors:  Claire Hirst; Gillian Ingram; Owen Pearson; Trevor Pickersgill; Neil Scolding; Neil Robertson
Journal:  J Neurol       Date:  2008-01-23       Impact factor: 4.849

10.  Database for serial magnetic resonance imaging in multiple sclerosis.

Authors:  F Barkhof; A J Thompson; L Kappos; J J Nauta; T Yousri; I Berry; G Scotti; B Appel; P S Tofts; D H Miller
Journal:  Neuroradiology       Date:  1993       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.